Benefits of a new testosterone gel formulation for hypogonadal men.
Hypogonadism is a common problem in men. It affects 2% to 30% of men aged 40 to 59 years, 20% to 45% aged 60 to 69 years, 34% to 70% aged 70 to 79 years, and most men aged >80 years. Hypogonadism is also highly prevalent in men with chronic illnesses, such as HIV infection. The low testosterone (T) levels associated with hypogonadism impair sexual function and many other aspects of health and well-being. In aging men and in those who are chronically ill, impaired gonadal function is characterized by subtle changes at many stages of T regulation. T therapy reverses the effects of hypogonadism, improving sexual function, body composition, mood, and well-being. Although many forms of T therapy are available, some therapies have limitations that render them ineffective or inconvenient. A new type of T gel has improved pharmacokinetic and clinical profiles compared with other forms of T therapy. This T gel has been shown to be effective in older men and in men with HIV infection, despite unsatisfactory response to earlier T-gel therapy.
Kaminetsky
Jed C
JC
Department of Urology NewYork University Medical Center, New York, New York 10016, USA. jckammd@worldnet.att.net
D000728:Androgens / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005782:Gels; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy*; D008297:Male; D013739:Testosterone / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome
D000728:Androgens; D005782:Gels; D013739:Testosterone